Elucidation of the effect of Omega-3-Acid ethyl esters for CKD patients with dyslipidemia, compared to ethyl icosapentate

Elucidation of the effect of Omega-3-Acid ethyl esters for CKD patients with dyslipidemia, compared to ethyl icosapentate - Elucidation of the effect of Omega-3-Acid ethyl esters for CKD patients with

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013149

Enrollment

100

Registered

2014-02-13

Start date

2014-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD patients with dyslipidemia

Interventions

switch to omega 3 fatty acids

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) chronic kidney disease patients with dyslipidemia 2) patients under the medical treatment with Epadel 3) patient who is competent to understand the aim of this study and agree on it

Exclusion criteria

Exclusion criteria: 1) Patients who are bleeding 2) Past medical history of hypersensitivity to Lotriga 3) Judged as ineligible by physicians

Design outcomes

Primary

Measure	Time frame
(F) LDL, HDL, (F) LDL / HDL ratio, total cholesterol, triglyceride, proteinuria (urinary albumin), sCr, eGFR, urinary L-FABP at 0, 3, and 6 months after starting of treatment	—

Secondary

Measure	Time frame
QOL questionnaire, Quadrant blood fatty acid (EPA / AA ratio, DHA / AA ratio), Oxidized LDL, high-sensitivity CRP, urinary 8-OHDG, ADMA	—

Countries

Japan

Contacts

Public ContactHitoshi Suzuki

Juntendo University Faculty of Medicine Department of Internal Medicine, Division of Nephrology

shitoshi@juntendo.ac.jp03-5802-1065

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026